Senseonics Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.
August 07 2020 - 8:00AM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM)
system for people with diabetes, today announced Highmark Inc. will
begin providing coverage for the Eversense CGM effective September
28, 2020. This coverage decision adds to the growing number of
payers who are writing Eversense into their CGM coverage policies,
as well as paying for the healthcare provider’s time for the
in-office sensor placement.
Highmark is among the top 10 largest health insurers in the
United States, providing plans to residents across Pennsylvania,
West Virginia and Delaware as an independent licensee of the Blue
Cross Blue Shield Association. The organization provides plans to
over 5.6 million members and is the largest healthcare insurer in
Pennsylvania and the fourth-largest overall Blue Cross Blue Shield
affiliate.
“Creating access to our CGM technology for diabetes patients
through broad-based reimbursement is a priority for ensuring the
long-term success of Eversense and our next-generation systems,”
said Tim Goodnow, PhD, President and CEO of Senseonics. “It is
encouraging to see the growing number of healthcare plans that
recognize the value of our differentiated long-term implantable
system and the benefits it provides to patients. We are pleased
with this recent success and with our progress increasing patient
access to date.”
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration twice per day, and
when symptoms do not match CGM information or when taking
medications of the tetracycline class. The sensor insertion and
removal procedures are performed by a health care provider. The
Eversense CGM System is a prescription device; patients should talk
to their health care provider to learn more. For important safety
information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200807005102/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Mirasol Panlilio 301-556-1631
Mirasol.panlilio@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jul 2023 to Jul 2024